Entrada Therapeutics (TRDA) EBT Margin (2023 - 2026)
Entrada Therapeutics' (TRDA) quarterly EBT Margin came in at 4534.74% in Q1 2026, down 445035.0% year-on-year from N/an in Q1 2025, and down 50.76% quarter-over-quarter from 3007.85% in Q4 2025.
Entrada Therapeutics (TRDA) EBT Margin (2023 - 2026) Analysis & Trends
Entrada Therapeutics' EBT Margin history runs 4 years deep, the most recent figure standing at 4534.74% for Q1 2026.
- On a quarterly basis, EBT Margin fell 445035.0% year-over-year to 4534.74% in Q1 2026; TTM through Mar 2026 was 2878.29%, a 289211.0% decrease from a year earlier, with the FY2025 full-year figure at 561.84%, down 59338.0% from the prior year.
- EBT Margin slipped to 4534.74% in Q1 2026 per TRDA's latest filing, from 3007.85% in the prior quarter.
- Across five years, EBT Margin topped out at 61.03% in Q2 2024 and bottomed at 4534.74% in Q1 2026.
- The 4-year median for EBT Margin is 66.49% (2023), against an average of 962.85%.
- Across the five-year window, EBT Margin soared 12752 bps in 2024 and tumbled 445035 bps in 2026, its largest moves.
- Year by year, EBT Margin stood at 21.98% in 2023, then slumped by 109 bps to 1.98% in 2024, then tumbled by 152116 bps to 3007.85% in 2025, then plunged by 51 bps to 4534.74% in 2026.
- Per Business Quant, the three latest TRDA EBT Margin figures stand at 4534.74% (Q1 2026), 3007.85% (Q4 2025), and 2693.93% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Entrada Therapeutics | 253.11 Mn | 253.11 Mn | - | -4,534.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,534.74% |
| Dec 31, 2025 | -3,007.85% |
| Sep 30, 2025 | -2,693.93% |
| Jun 30, 2025 | -2,201.28% |
| Mar 31, 2025 | -84.39% |
| Dec 31, 2024 | -1.98% |
| Sep 30, 2024 | -81.21% |
| Jun 30, 2024 | 61.03% |
| Mar 31, 2024 | 42.84% |
| Dec 31, 2023 | 21.98% |
| Sep 30, 2023 | 41.30% |
| Jun 30, 2023 | -66.49% |
| Mar 31, 2023 | -12.36% |